Cargando...
Meloxicam methyl group determines enzyme specificity for thiazole bioactivation compared to sudoxicam
Meloxicam is a thiazole-containing NSAID that was approved for marketing with favorable clinical outcomes despite being structurally similar to the hepatotoxic sudoxicam. Introduction of a single methyl group on the thiazole results in an overall lower toxic risk, yet the group’s impact on P450 isoz...
Guardado en:
| Publicado en: | Toxicol Lett |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7807415/ https://ncbi.nlm.nih.gov/pubmed/33253783 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.toxlet.2020.11.015 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|